Mesothelioma Treatment in California

Top California Mesothelioma Cancer Centers

The best cancer centers for mesothelioma treatment in California are NCI-Designated comprehensive cancer centers, university hospitals and California research centers that provide access to cutting-edge medical care. The UCLA Jonsson Comprehensive Cancer Center in Los Angeles offers some of the best multidisciplinary care in the state along with new mesothelioma clinical trials. Military veterans in California can receive excellent mesothelioma care covered by the U.S. Department of Veterans Affairs at the West Los Angeles VA Medical Center.

Patients with peritoneal and pleural mesothelioma can find advanced surgical, radiation and medical oncology treatments at the Ridley-Tree Cancer Center in Santa Barbara. In 2022, Ridley-Tree had nearly 400 patients enrolled across 57 clinical trials.

Jonsson Comprehensive Cancer Center, mesothelioma treatment center

UCLA Jonsson Comprehensive Cancer Center

10833 Le Conte Ave Los Angeles, CA 90024

Ridley-Tree Cancer Center

540 W Pueblo St, Santa Barbara, CA 93105

Samuel Oschin Cancer Center at Cedars-Sinai

8700 Beverly Blvd, Los Angeles, CA 90048

VA West Los Angeles Medical Center

11301 Wilshire Blvd Los Angeles CA 90073

UC San Diego Moores Cancer Center

3855 Health Sciences Dr., La Jolla, CA 92093

Stanford Cancer Institute

875 Blake Wilbur Dr, Stanford CA 94305

UCSF Helen Diller Family Comprehensive Cancer Center

1600 Divisadero St, San Francisco, CA 94115

City of Hope

1500 East Duarte Road Duarte, California 91010

Locations of California’s Top Cancer Centers

Patients have access to high-quality mesothelioma treatment in Los Angeles, San Diego, San Francisco, Santa Barbara and other large cities. Families that live in Northern California can access cutting-edge treatment options at the NCI-Designated UC Davis Comprehensive Cancer Center in Sacramento and Stanford Cancer Institute near San Jose. In the Greater Los Angeles Area, patients can find the best California mesothelioma doctors at the UCSF Helen Diller Family Comprehensive Cancer Center and the Samuel Oschin Cancer Center at Cedars-Sinai.

All Centers (11)

City of Hope
East Duarte Road
Duarte, CA 91010
- NCI-Designated Cancer Center
Directions
Kaiser Permanente Oakland Medical Center
3600 Broadway
Oakland, CA 94611
- Center of Excellence
Directions
Ridley-Tree Cancer Center
540 W Pueblo St
Santa Barbara, CA 93105

Directions
Samuel Oschin Cancer Center at Cedars-Sinai
8700 Beverly Blvd
Los Angeles, CA 90048

Directions
Stanford Cancer Institute
875 Blake Wilbur Dr
Stanford, CA 94305
- NCI-Designated Cancer Center
Directions
UC Davis Comprehensive Cancer Center
2279 45th St.
Sacramento, CA 95817
- Center of Excellence
- NCI-Designated Cancer Center
Directions
UC San Diego Moores Cancer Center
3855 Health Sciences Dr
La Jolla, CA 92093
- NCI-Designated Cancer Center
Directions
UCLA Health
Westwood Plaza
Los Angeles, CA 90095

Directions
UCLA Jonsson Comprehensive Cancer Center
10833 Le Conte Ave
Los Angeles, CA 90024
- Center of Excellence
- NCI-Designated Cancer Center
Directions
UCSF Helen Diller Family Comprehensive Cancer Center
1600 Divisadero St
San Francisco, CA 94115
- NCI-Designated Cancer Center
Directions
VA West Los Angeles Medical Center
11301 Wilshire Blvd
Los Angeles, CA 90073
- VA Hospital
Directions

Top Doctors in California

Dr. W. Charles Conway at Ridley-Tree Cancer Center is an expert in treating peritoneal mesothelioma. As a top mesothelioma doctor in Santa Barbara, Dr. Conway performs cytoreductive surgery with heated chemotherapy, one of the best treatment options for peritoneal mesothelioma. Dr. Robert Cameron is one of the nation’s most respected thoracic surgeons and a leading mesothelioma doctor in Los Angeles.

Robert B. Cameron

Pleural Specialist | Thoracic Surgery

Expertise:

Pleurectomy and Decortication Clinical Trials

UCLA Jonsson Comprehensive Cancer Center • Los Angeles, California

View Profile

Expertise:

Pleurectomy and Decortication Clinical Trials

UCLA Jonsson Comprehensive Cancer Center

Los Angeles, California

View Profile

Dr. Robert B. Cameron developed a lung-sparing surgery for pleural mesothelioma that not only extends survival but offers greater quality of life by preserving the lung. Cameron’s surgery has a lower risk of complications and studies report longer survival times.

Read Bio

W. Charles Conway

Peritoneal Specialist | Surgical Oncology

Expertise:

Peritoneal Mesothelioma Thoracic Diseases Cytoreductive Surgery and HIPEC

Ridley-Tree Cancer Center • Santa Barbara, California

View Profile

Expertise:

Peritoneal Mesothelioma Thoracic Diseases Cytoreductive Surgery and HIPEC

Ridley-Tree Cancer Center

Santa Barbara, California

View Profile

Dr. W. Charles Conway is an expert in peritoneal mesothelioma and the Director of Surgical Oncology at Ridley-Tree Cancer Center in Santa Barbara, California. He specializes in minimally invasive robotic surgery and heated chemotherapy for peritoneal mesothelioma.

Read Bio

Harmik Soukiasian

Pleural Specialist | Thoracic Surgery

Expertise:

Robotic Surgery Lung Cancer

Samuel Oschin Cancer Center at Cedars-Sinai • Los Angeles, California

View Profile

Expertise:

Robotic Surgery Lung Cancer

Samuel Oschin Cancer Center at Cedars-Sinai

Los Angeles, California

View Profile

Dr. Harmik Soukiasian is the lead surgeon in Cedars-Sinai’s Mesothelioma Program, which specializes in early detection, novel treatments and clinical trials. His expertise includes video-assisted thoracoscopic surgery and photodynamic therapy.

Read Bio

Robert M. Barone

Peritoneal Specialist | Surgical Oncology

Expertise:

Cytoreductive Surgery HIPEC

Sharp Memorial Hospital • San Diego, California

View Profile

Expertise:

Cytoreductive Surgery HIPEC

Sharp Memorial Hospital

San Diego, California

View Profile

Dr. Robert Barone is the esteemed director of Surgical Oncology Services for Sharp Healthcare in San Diego, specializing in the treatment of peritoneal mesothelioma cancer.

Read Bio

Find a Specialist Near You

Type of Mesothelioma

Specialty

Language

Searching…

Clinical Trials in California

California is widely recognized for cancer research and mesothelioma cancer centers, including mesothelioma clinical trials and laboratory research at organizations like the University of California San Francisco. The Pacific Mesothelioma Center, which is under the medical direction of Dr. Cameron, conducts ongoing research to develop new therapies. Mesothelioma clinical trials in California can let patients access new cancer treatments or emerging therapies.

NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose

Locations

NCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.

Locations

NCT04665206

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Locations

NCT05647265

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.

Locations

NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Locations

NCT05873686

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Locations

NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Locations

NCT06251310

SW-682 in Advanced Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.

Locations

NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Locations

NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

Locations

NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Locations

NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Locations

NCT05732831

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Locations

Financial Support for Treatment in California

There are several financial support options available in California for mesothelioma patients and caregivers, especially for families with low income, inadequate insurance or maxed-out benefits. Nonprofits like Cancer Support Community and Cancer Angels of San Diego can provide emergency financial aid, help with basic needs and assistance with travel or lodging. Some California oncology centers can completely cover treatment costs for cancer patients who fall under maximum income requirements, including the UCSF Helen Diller Family Comprehensive Cancer Center and the Stanford Cancer Institute.

Financial Resources for California Mesothelioma Patients

Cancer Angels of San Diego: CASD helps Stage IV cancer patients with financial aid for daily living essentials, such as rent, utility payments, groceries and childcare expenses. The nonprofit supports patients in San Diego County who have any type of Stage IV cancer, including mesothelioma.
Cancer CAREpoint: This San Jose nonprofit provides a variety of free services and resources to cancer patients, caregivers and family members, including short-term financial assistance and personalized wig support. In 2025, Cancer CAREpoint distributed nearly $90,000 in emergency financial aid to 328 individuals.
Cancer Support Community San Francisco Bay Area: When funds are available, this organization offers emergency financial aid to low-income cancer patients in the Bay Area. Caregivers can also qualify for a grant, but only the patient’s medical care provider can apply.
City of Hope: Both the NCI-Designated City of Hope location in Los Angeles and the Orange County cancer center may agree to fully cover medical care costs for California mesothelioma patients who make less than 600% of the Federal Poverty Level guidelines, which was $7,290 a month in 2023.
Organic Soup Kitchen: As part of Organic Soup Kitchen’s Cancer Recovery Program, volunteers in Santa Barbara County prepare and deliver nutrient-dense soup meals every week at no cost to low-income cancer patients. The California cancer nonprofit partners with local organizations and farmers to source organic produce, such as Trinity Gardens and Veggie Rescue.
UC Davis Foundation: The UC Davis Comprehensive Cancer Center Patient Assistance Fund provides financial assistance for some cancer patients while they undergo treatment. The fund can cover the cost of medical supplies, nearby lodging, transportation, food and other essentials.

Mesothelioma patients can also speak with a Patient Advocate to learn about additional financial resources. For example, U.S. veterans diagnosed with mesothelioma may be eligible for disability compensation, survivor benefits and other VA benefits. Our Veterans Department helps patients file claims and navigate the approval process, which can be complex.

Cancer Resources in California

Mesothelioma patients in California can take advantage of support services for physical, emotional and mental well-being. Local organizations such as UCLA Health and Cancer Support Community have programs for pain management, counseling services, cancer rehabilitation, meal assistance and caregiver support groups.

Support Services for Mesothelioma Patients in California

Helen’s Room: Helen’s Room is a nonprofit organization based in Los Angeles, California. It provides appearance resources for cancer patients who live in the Los Angeles area, such as wigs and private fitting consultations. All services and products are free for uninsured, low-income women with cancer.
Hoag Family Cancer Institute: The Hoag Family Cancer Institute in Newport Beach offers a long list of support services for patients in every stage of treatment. Available programs include financial navigation, exercise, spiritual care, oncology massage and rehabilitation services.
Stanford Health Care Cancer Supportive Care Program: Stanford Health Care sponsors workshops and resources for patients. It has locations in Palo Alto, South Bay and Redwood City. Patients can attend classes to learn more about cancer treatment.
Triumph Cancer Foundation: This Sacramento-based nonprofit provides a free 12-week exercise program to cancer survivors in the Greater Sacramento Metro Area. Each Triumph Fitness session lasts 90 minutes, and there are in-person and virtual classes available. Cancer exercise specialists provide personalized recommendations to help survivors improve flexibility, muscle mass and energy levels.
Cancer Support Community: Cancer Support Community offers a network of free services throughout California, including emotional support groups for patients, caregivers and surviving family members. The organization focuses on helping patients cope with cancer treatment and hosts monthly events to connect patients with resources.

Many California mesothelioma patients can also call 211 to connect with local support services in dozens of counties across the state, from San Diego and Monterey to Humboldt and San Bernardino County. Transportation, food assistance and home care resources are all available through this free service

What Survivors Say About Their Mesothelioma Treatment in California

The stories that local mesothelioma patients and family members have shared with us show that mesothelioma doctors in California make an enormous difference in the lives of patients, survivors and caregivers. From groundbreaking clinical trials at the University of California in San Diego to treatment and support therapies at UCSF, NCI-designated cancer centers in California have helped mesothelioma patients find excellent care strategies and enjoy more time with loved ones.

Survivor Experience

“I was a fortunate one. It’s still in the back of your mind that it may recur — and it probably will — but hopefully science will catch up to it before it does. In the meantime, I have things I want to do.”

Jim H. , Pleural Mesothelioma Survivor

Verified Asbestos.com Survivor

Survivor Experience

“I don’t know exactly why I’m doing so well. I must have a great immune system that works well with this therapy. I know the mesothelioma is there, but I just try and ignore that fact,” he said. “There are days when I think about it, but I try to stay busy, try to stay positive all the time. And for now, it’s working.”

– Andy A. , Pleural Mesothelioma Survivor

Verified Asbestos.com Survivor